MX2023010258A - Biomarcadores para la terapia del cancer usando antagonistas de mdm2. - Google Patents

Biomarcadores para la terapia del cancer usando antagonistas de mdm2.

Info

Publication number
MX2023010258A
MX2023010258A MX2023010258A MX2023010258A MX2023010258A MX 2023010258 A MX2023010258 A MX 2023010258A MX 2023010258 A MX2023010258 A MX 2023010258A MX 2023010258 A MX2023010258 A MX 2023010258A MX 2023010258 A MX2023010258 A MX 2023010258A
Authority
MX
Mexico
Prior art keywords
pathway
biomarkers
ddr
mdm2 antagonist
cancer
Prior art date
Application number
MX2023010258A
Other languages
English (en)
Spanish (es)
Inventor
Harpreet Kaur Saini
Nicola Ferrari
Jong Sook Ahn
Jessica Laura Brothwood
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of MX2023010258A publication Critical patent/MX2023010258A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/91045Acyltransferases (2.3)
    • G01N2333/91074Aminoacyltransferases (general) (2.3.2)
    • G01N2333/9108Aminoacyltransferases (general) (2.3.2) with definite EC number (2.3.2.-)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2023010258A 2021-03-04 2022-03-04 Biomarcadores para la terapia del cancer usando antagonistas de mdm2. MX2023010258A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2103080.4A GB202103080D0 (en) 2021-03-04 2021-03-04 Cancer biomarkers
PCT/IB2022/051906 WO2022185260A1 (en) 2021-03-04 2022-03-04 Biomarkers for cancer therapy using mdm2 antagonists

Publications (1)

Publication Number Publication Date
MX2023010258A true MX2023010258A (es) 2023-09-12

Family

ID=75339986

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010258A MX2023010258A (es) 2021-03-04 2022-03-04 Biomarcadores para la terapia del cancer usando antagonistas de mdm2.

Country Status (13)

Country Link
US (1) US20240293364A1 (https=)
EP (1) EP4301875A1 (https=)
JP (1) JP2024508895A (https=)
KR (1) KR20230150285A (https=)
CN (1) CN117295825A (https=)
AU (1) AU2022230312A1 (https=)
BR (1) BR112023017572A2 (https=)
CA (1) CA3205532A1 (https=)
GB (1) GB202103080D0 (https=)
IL (1) IL304375A (https=)
MX (1) MX2023010258A (https=)
TW (1) TW202302087A (https=)
WO (1) WO2022185260A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
WO2023134707A1 (en) * 2022-01-11 2023-07-20 Ascentage Pharma (Suzhou) Co., Ltd. Methods for treating aml-mrc and mds
WO2024243078A1 (en) * 2023-05-19 2024-11-28 Leapfrog Bio, Inc. Hsp90 inhibitors for the treatment of cancer
TW202540077A (zh) * 2023-11-16 2025-10-16 日商大塚製藥股份有限公司 具有抗癌活性之mdm2-p53交互作用的異吲哚啉酮抑制劑的中間體的製造方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
EP0951541B1 (en) 1995-07-31 2005-11-30 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
UA107814C2 (uk) 2009-11-12 2015-02-25 Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган Спірооксіндольні антагоністи мdм2
WO2011058367A2 (en) * 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
UY34591A (es) 2012-01-26 2013-09-02 Novartis Ag Compuestos de imidazopirrolidinona
EP2958893B1 (en) 2013-02-21 2017-05-03 F. Hoffmann-La Roche AG Asymmetric synthesis of a substituted pyrrolidine-2-carboxamide
CN105358530A (zh) 2013-06-10 2016-02-24 美国安进公司 制备mdm2抑制剂的方法及其结晶形式
BR112015029976A2 (pt) 2013-06-24 2017-07-25 Hoffmann La Roche formulação farmacêutica, formulação liofilizada farmacêutica e preparações novas, métodos e usos
KR20220136454A (ko) 2013-09-04 2022-10-07 다이이찌 산쿄 가부시키가이샤 스피로옥시인돌 유도체의 제조 방법
US9657351B2 (en) 2013-12-06 2017-05-23 Hoffman-La Roche Inc. MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist
BR122022015241B1 (pt) 2013-12-20 2023-09-26 Astex Therapeutics Limited Compostos heterocíclicos bicíclicos intermediários para a preparação de um composto de fórmula (i)
CA2945527C (en) 2014-04-17 2022-05-17 The Regents Of The University Of Michigan Mdm2 inhibitors and therapeutic methods using the same
JP2017532959A (ja) * 2014-10-09 2017-11-09 第一三共株式会社 Mdm2阻害剤に対する感受性の遺伝子シグネチャーに基づく予測因子に関するアルゴリズム
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
SG11201808728QA (en) 2016-04-06 2018-11-29 Univ Michigan Regents Mdm2 protein degraders
US10759808B2 (en) 2016-04-06 2020-09-01 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
WO2017205786A1 (en) 2016-05-27 2017-11-30 Aileron Therapeutics, Inc. Cell permeable peptidomimetic macrocycles
GB201704965D0 (en) * 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
CA3050645A1 (en) * 2018-07-27 2020-01-27 Ottawa Hospital Research Institute Treatment of acute myeloid leukemia
EP3814525A4 (en) * 2019-02-24 2022-04-13 Ascentage Pharma (Suzhou) Co., Ltd. TREATMENT METHODS AND BIOMARKERS FOR MDM2 INHIBITORS
GB201919219D0 (en) * 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers

Also Published As

Publication number Publication date
WO2022185260A1 (en) 2022-09-09
JP2024508895A (ja) 2024-02-28
CA3205532A1 (en) 2022-09-09
IL304375A (en) 2023-09-01
KR20230150285A (ko) 2023-10-30
AU2022230312A9 (en) 2025-03-13
AU2022230312A1 (en) 2023-07-13
GB202103080D0 (en) 2021-04-21
CN117295825A (zh) 2023-12-26
EP4301875A1 (en) 2024-01-10
TW202302087A (zh) 2023-01-16
BR112023017572A2 (pt) 2023-10-10
US20240293364A1 (en) 2024-09-05

Similar Documents

Publication Publication Date Title
MX2023010258A (es) Biomarcadores para la terapia del cancer usando antagonistas de mdm2.
MX2018008266A (es) Dinucleotidos ciclicos para tratar condiciones asociadas con actividad del estimulador de genes del interferon (sting) tales como cancer.
NI201700035A (es) Uso de paneles de genes mutantes del fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor del fgfr
BR112021010354A2 (pt) Métodos para o tratamento usando terapia celular adotiva
CO2022015650A2 (es) Conjugados de anticuerpo-fármaco que comprenden agonistas de sting
MX2021011209A (es) Novedosos inhibidores de molécula pequeña de factores de transcripción tead.
BR112018072197A2 (pt) amplificação de emparelhamento optimizado múltiplo (moma) - pcr de tempo real para avaliar o poço fetal
MX2021003457A (es) Composiciones y métodos para la edición génica de lactato deshidrogenasa (ldha).
AR102518A1 (es) Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40
CL2023003123A1 (es) Métodos de identificación de pacientes con posibilidad de beneficiarse de tratamiento con inhibidor de telomerasa
WO2020227159A3 (en) Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
BR112019002035A2 (pt) tratamento de câncer usando um receptor de antígeno quimérico em combinação com um inibidor de uma molécula pró-macrófago m2
BR112018072195A2 (pt) amplificação de incompatibilidade otimizada multiplexado (moma) - pcr de tempo real para avaliar o câncer
MX2021014455A (es) Inhibidores de proteina cinasas dependientes de adn.
ES2618506T3 (es) Marcador epigenético para la identificación de linfocitos T CD3CD4 positivos
MX2013006075A (es) Deteccion de aberraciones geneticas o moleculares asociadas con el cancer.
MY162056A (en) Diagnosis and treatment of cancer using anti -ereg antibody
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
BR112013021675A2 (pt) compostos de triazolopiridina como inibidores de pim cinase
BR112013018744A2 (pt) método para produzir um polipetídeo ou uma proteína recombinante
BR112023006305A2 (pt) Métodos e composições de terapia gênica com placofilina-2
MX2024003980A (es) Ensayos y metodos para seleccionar un regimen de tratamiento para un sujeto con leucemia.
ECSP24036299A (es) Composiciones y métodos para inhibir la expresión de la proteína angiotensinógeno (agt)
AR100157A1 (es) Composiciones y métodos para mejorar y/o predecir la amplificación de adn
MX2024001734A (es) Metodo de modificacion de diferenciacion e inmunidad de macrofagos.